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Impact of small vessel disease in 
the brain on gait and balance
Daniela Pinter1, Stuart J. Ritchie2,3, Fergus Doubal2,4, Thomas Gattringer1, Zoe Morris4,5, 
Mark E. Bastin4,5, Maria del C. Valdés Hernández4,5, Natalie A. Royle4,5, Janie Corley2,3, 
Susana Muñoz Maniega4,5, Alison Pattie2,3, David A. Dickie4,5, Julie Staals6, Alan J. Gow2,7, 
John M. Starr2,8, Ian J. Deary2,3, Christian Enzinger1,9, Franz Fazekas1 & Joanna Wardlaw2,4,5
Gait and balance impairment is highly prevalent in older people. We aimed to assess whether and how 
single markers of small vessel disease (SVD) or a combination thereof explain gait and balance function 
in the elderly. We analysed 678 community-dwelling healthy subjects from the Lothian Birth Cohort 
1936 at the age of 71–74 years who had undergone comprehensive risk factor assessment, gait and 
balance assessment as well as brain MRI. We investigated the impact of individual SVD markers (white 
matter hyperintensity – WMH, microbleeds, lacunes, enlarged perivascular spaces, brain atrophy) as 
seen on structural brain MRI and of a global SVD score on the patients’ performance. A regression model 
revealed that age, sex, and hypertension significantly explained gait speed. Among SVD markers white 
matter hyperintensity (WMH) score or volume were additional significant and independent predictors of 
gait speed in the regression model. A similar association was seen with the global SVD score. Our study 
confirms a negative impact of SVD-related morphologic brain changes on gait speed in addition to age, 
sex and hypertension independent from brain atrophy. The presence of WMH seems to be the major 
driving force for SVD on gait impairment in healthy elderly subjects.
Gait and balance impairment is highly prevalent in older people, restricts independence and increases the risk of 
falls, institutionalization and mortality1. Impairment increases rapidly in prevalence from around 15% at the age 
of 60 to > 50% in individuals aged 80 years and older2–4. Besides increasing age, there are multiple contributing fac-
tors causing gait and balance disturbances, including vascular risk factors (e.g. high blood pressure or diabetes)5,6. 
Occurrence of cerebrovascular disease in the elderly, particularly of cerebral small vessel disease (SVD), also 
appears to play some role in the development of gait and balance impairment7–9. Cerebral SVD refers to a group 
of pathological processes with various aetiologies7 which appear on magnetic resonance imaging (MRI) as white 
matter hyperintensities (WMH), microbleeds, lacunes of presumed vascular origin and enlarged perivascular 
spaces (PVS)7,10–12. SVD has also been suggested to cause brain volume loss13,14, but defined cut-offs regarding 
whether atrophy is related to “normal” aging or SVD are missing. Nevertheless, total brain volume could act as an 
important mediator in the relation between SVD and gait or balance function15 and needs to be considered when 
examining the impact of SVD features on gait and balance function.
Despite being the second most common problem after impaired cognitive functioning16, gait and balance 
disturbances have rarely been a target outcome variable in large population-based studies examining the clinical 
consequences of SVD17. Moreover most investigations have focused only on the association between gait and 
balance impairment with single MRI markers of SVD15,18–22. Hence, it is unclear whether the strength of the 
association with disturbed gait and balance varies between individual features of SVD as they reflect distinct 
pathologies with a possibly different impact on brain function. Alternatively, and if they exerted additive damag-
ing effects, a simple sum score of SVD markers could capture the burden from cerebral changes induced by SVD 
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in a more global manner and provide more robust associations as recently shown for the relation between SVD 
and cognitive impairment23,24.
With these considerations we aimed to (a) demonstrate the potential link between distinct SVD MRI markers 
and gait or balance function in healthy subjects. (b) Furthermore, we explored the differential link between single 
versus combined SVD markers on gait and balance function. Due to the fact, that multiple variables could lead to 
gait and balance impairment in healthy elderly subjects, we additionally examined (c) the impact of single versus 
combined SVD markers beyond demographics, risk factors and atrophy. As different parameters (e.g. a simple 
visual rating scale vs. volumetric assessment)25 might be used to describe WMH burden, we included both visual 
rating and volumetric data in our analyses. To reduce confounding effects, we investigated these questions in a 
cohort of independent community-dwelling healthy older subjects with the same year of birth.
Methods
Participants. Data of 866 community-dwelling healthy subjects from the Lothian Birth Cohort 1936 
(LBC1936) were available for this investigation. More detailed information of the recruitment and study proce-
dure can be found in Deary et al.26,27. 680 (79%) of those individuals had undergone comprehensive risk factor 
assessment, gait and balance assessment, as well as brain MRI and thus could be used for our analyses. The main 
loss of subjects was in those who opted not to have a brain MRI or if the MRI data was not suitable. Two further 
participants were excluded because of a diagnosis of Parkinson’s disease, leaving a final sample of 678 subjects. 
Assessments used for the present study were performed at a visit at about age 73 (age range = 70.96 to 74.21 
years).
Standard protocol approvals, registrations, and patient consents. Ethics permission for the study 
protocol was obtained from the Multi-Centre Research Ethics Committee for Scotland (MREC/01/0/56) and 
from Lothian Research Ethics Committee (LREC/2003/2/29). Experimental protocols were approved by the 
Multi-Centre Research Ethics Committee for Scotland (MREC/01/0/56) and Lothian Research Ethics Committee 
(LREC/2003/2/29). The research was carried out in compliance with the Helsinki Declaration. All experiments 
were performed in accordance with relevant guidelines and regulations. All participants gave written, informed 
consent.
General assessment. An extensive description of all variables obtained for the LBC1936 study can be found 
in Deary et al.26 for clinical and Wardlaw et al.28 for imaging variables. All participants underwent a medical 
interview and physical examination. Disease history and vascular risk factors (e.g. smoking, high blood pressure, 
diagnosis of diabetes, high cholesterol) were obtained in a structured interview.
Assessment of gait and balance function. Gait speed was assessed by the six-meter walk test, a common 
assessment used in research studies to access physical function. Furthermore, two subtests (chair-stands and 
standing balance) of the Short Physical Performance Battery were applied. Please see Supplementary Information 
for more details.
Brain MRI acquisition. The brain imaging protocol for the study has been described previously28. All partic-
ipants were scanned on a General Electric 1.5 T clinical MRI scanner (Signa Horizon HDx) operating in research 
mode. For this study, we used axial T2, T2*, fluid-attenuated inversion recovery (FLAIR) and T1-weighted 
sequences.
MRI rating and composition of SVD score. MRI images were rated for the presence of WMH, perivas-
cular spaces (PVS), microbleeds and lacunes using a standardized protocol, with validated visual scales and these 
ratings also served to create a global SVD scale ranging from 0–4 as described previously12,24,29–31. In short, deep 
WMH and periventricular hyperintensities (PVH) were graded on the Fazekas scale (each 0–3) using FLAIR- 
and T2-weighted sequences and one point was awarded on the SVD scale when early confluent to confluent deep 
WMH (WMH score 2 or 3) and/or irregular PVH extending into the deep white matter (PVH score 3) were pres-
ent. PVS defined as small (< 3 mm) punctate hyperintensities on T2-weighted images were rated from 0 (absent) 
to 4 (severe) and one point on the SVD scale was awarded when moderate to severe (grade 2–4) PVS in the basal 
ganglia were present. Microbleeds (CMB) were defined as small (< 10 mm), homogeneous, round foci of low 
signal intensity on T2*-weighted images and the presence of one or more CMB gave one point on the SVD scale. 
Lacunes were defined as small (< 20 mm in diameter), subcortical lesions of similar signal to CSF and ≥ 1 lacune 
was one point on the SVD scale. We also assessed the WMH volume in cm3 32 and calculated the brain volume 
normalized by intracranial volume28,33.
Statistical Analysis: with gait. We used the Statistical Package of Social Science (IBM SPSS Statistics 23, 
SPSS Inc., Chicago, Illinois, USA) for T-Tests, nonparametric analysis (e.g. Mann-Whitney U for standing bal-
ance) and correlation analysis. First we examined the associations between demographic and vascular risk factor 
variables (e.g. sex, age, smoking), atrophy (NBV) and SVD markers with the dependent variables (gait speed, 
chair-stands test or standing balance) using Pearson correlation, Spearman correlation or point-biserial corre-
lation. To investigate the association of the individual SVD markers and of the global SVD score or of WMH 
volume withgait speed and chair-stands, we applied hierarchical linear regression analysis. We controlled for sex 
and age in the first step of our hierarchical regression analysis, and vascular risk factor variables in the second 
step, adding MRI-parameters in the third step. A negative binomial regression analysis was used for prediction 
of standing balance function. The level of significance was set at 0.05. Bonferroni-adjusted level of significance is 
indicated were applicable.
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Results
Sample characteristics. Table 1 gives information on the demographics, risk factor variables and gait and 
balance function of the study sample. Table 2 provides a more detailed overview regarding the prevalence of 
single SVD markers and an overview on the MRI-characteristics of investigated individuals including the contri-
bution of the individual MRI markers to the global SVD score. Overall, most of the subjects had a SVD score of 0 
or 1 (80.8%), while scores 2–4 were less frequent (19.2%).
Univariate correlations of gait speed, chair-stands and balance test with demographics, risk 
factors and SVD related abnormalities. Regarding demographics and risk factors, correlational analysis 
showed that gait speed was significantly slower in older subjects, females, subjects with high blood pressure (HBP) 
or diabetes (see Table S1 in the Supplementary Information). Furthermore, performance on the chair-stands test 
was significantly worse in older subjects, smokers and subjects with diabetes. Standing balance was significantly 
worse in female subjects, subjects with HBP or diabetes.
Regarding focal SVD related abnormalities and normalized brain volume (NBV), correlational analysis 
showed that gait speed was significantly slower in subjects with higher WMH and PVS scores, higher WMH vol-
ume, lower NBV and a higher global SVD score (see Table S2 in the Supplementary Information). Furthermore, 
performance on the chair-stands test was worse in subjects with higher WMH score and a higher global SVD 
score. Performance on the standing balance test was worse in subjects with higher WMH volume and a higher 
global SVD score.
Association of SVD related abnormalities with gait speed, chair-stands and balance test. Using 
a linear regression analysis model to assess the contribution of individual SVD markers to patients’ performance 
only the WMH score (R2 = 1.3%) and WMH volume (R2 = 2.3%) were associated significantly with gait speed 
following Bonferroni-adjustment (Table 3). None of the other SVD markers (microbleeds, lacunes of presumed 
vascular origin, PVS) significantly predicted gait. Gait speed was also significantly and separately predicted by 
the global SVD score (R2 = 1.4%). Performance on the chair-stands test was predicted by the global SVD score 
(R2 = 0.6%) and the WMH score (R2 = 0.7%) but significance did not withstand Bonferroni-adjustment. The neg-
ative binomial regression model revealed no significant prediction of performance on the standing balance test 
from any SVD marker (Table 3).
Association of SVD related abnormalities with gait speed and balance function in addition 
to demographics, risk factors and atrophy. We used a hierarchical linear regression model to assess 
whether SVD markers independently predict gait speed, chair-stands and balance function in addition to sex, 
age, risk factors and NBV. The extended regression model revealed that age (age (p < 0.001; older subjects per-
formed worse) and sex (p < 0.001; women performed worse; R2 = 6.8%), as well as HBP (p = 0.003) significantly 
contributed to prediction of gait speed. Standardized beta-values (βj) and adjusted R2 (variance accounted for) 
are shown in Table 4. Incrementally, MRI-parameters added to the explanation. NBV and single SVD markers 
(WMH score or WMH volume) independently explained gait. The hierarchical regression model showed that in 
addition to NBV (p = 0.010), the WMH score (p = 0.010; ∆ R2 = 1.5%) and WMH volume (p = 0.001; ∆ R2 = 2.9%) 
independently added to prediction of gait speed. Similar scores were observed if single WMH markers were 
replaced by the global SVD score in the regression model (p = 0.003; ∆ R2 = 2.0%).
For the chair-stands test, none of the single SVD markers, be it single or combined, explained incremental 
variance after controlling for demographics (sex: p < 0.001, women performed worse; R2 = 0.1%), risk factors 
and NBV (Table 4). None of the demographic variables, risk factors and MRI parameters significantly predicted 
performance on the standing balance test.
Sensitivity analysis for subjects with moderate to severe SVD scores. To allow some compari-
son with previous cohort studies (e.g. LADIS, RunDMC)18–20, we also performed additional analysis including 
only subjects with moderate to severe (≥ 2) global SVD scores (N = 127). In this subsample demographics and 
Demographics N = 678 %
Sex, male, N (%) 359 52.9
Age in years 72.5 (0.7)
Risk factors N %
Smoking (current or ex), N (%) 359 52.9
High Blood Pressure, N (%) 332 48.9
Diabetes, N (%) 70 10.3
High Cholesterol, N (%) 284 41.9
Gait Speed and Balance function
 Gait speed (sec) 4.3 (1.2)
 Chair-Stands (sec) 13.7 (4.4)
 Standing balance (0–4) 3.8 (0.5)
Table 1.  Demographics, risk factors, gait and balance function of the study sample. Sample characteristics 
are presented as mean and standard deviation (SD in brackets) if not otherwise specified. N = number of 
subjects.
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risk factors did not significantly predict gait speed, whereas NBV (6%) and the global SVD score (6.4%) were 
significant in accounting for 12.4% of the variance (βj = 0.22, p = 0.013). WMH score (p = 0.216) and volume 
(p = 0.309) did not significantly explain gait speed in subjects with moderate to severe SVD. No variable signifi-
cantly explained performance on the chair-stands test or standing balance test.
Discussion
This study confirms that SVD-related brain changes are associated with worse performance in gait speed, the 
chair-stands test and standing balance in older independent community-dwelling subjects. Regression models 
showed that a single marker of SVD (i.e. the WMH score or WMH volume) and the global SVD score consistently 
explained gait speed (R2 = 1.3–2.3%). Results for the chair-stands test pointed in the same direction: The WMH 
score and the global SVD score were related to worse performance (R2 = 0.6–0.7%), but these results did not 
withstand Bonferroni-adjustment. No significant explanation of standing balance for any SVD marker (single or 
combined) was observed.
As expected demographics (e.g. sex, age) and risk factors (high blood pressure) had an impact on gait speed in 
healthy older subjects, but SVD related abnormalities still additionally explained changes in gait independently 
from atrophy. Overall, compared to previous studies the contribution to explain changes in gait speed appears 
rather low. There are two likely explanations for this finding:
First, in comparison to previous cohort studies (e.g. LADIS, RunDMC)18,20 which partly included neuro-
logic ‘patients’, our community-dwelling, non-disabled older subjects had relatively low SVD burden. 44.4% had 
a global SVD score of ‘zero’ indicating only minor individual SVD markers. While this certainly reduces the 
strengths of correlations it is thus reassuring that we could still confirm earlier findings of a correlation between 
SVD and gait and balance disorders in a group of individuals without possible confounders such as other 
MRI characteristics
Normalized Brain Volume (nIcV in %) 69 (1)
WMH volume (cm3) 12.19 (12.17)
WMH score deep WMH N %
0 104 15.3
1 430 63.4
2 124 18.3
3 20 2.9
WMH score perivent WMH
 0 21 3.1
 1 436 64.3
 2 178 26.3
 3 43 6.3
CMB
 0 599 88.3
 1–3 70 10.3
 > 3 9 1.4
Lacune
 0 639 94.2
 1 28 4.1
 ≥ 2 11 1.6
PVS in BG
 0 2 0.3
 1 402 59.3
 2 249 36.7
 3 24 3.5
 4 1 0.1
Score 1 on SVD scale N %
 SVD WMH (WMH score 2 or 3 in deep WMH &/or WMH score 3 in perivent WMH) 152 22.4
 SVD CMB (1 or more CMB) 79 11.7
 SVD lacune (1 or more lacunes) 39 5.8
 SVD PVS (grade 2–4 in BG) 274 40.4
Table 2.  MRI characteristics, prevalence of single SVD markers, SVD subscores and SVD specification 
of the study sample. Sample characteristics are presented as mean and standard deviation (SD in brackets) if 
not otherwise specified. BG = basal ganglia; Normalized Brain Volume (nIcV) = brain volume normalized by 
intracranial volume; lacune = lacune of presumed vascular origin, CMB = cerebral microbleeds, N = number of 
subjects, perivent = periventricular; PVS = perivascular spaces, WMH = white matter hyperintensities.
www.nature.com/scientificreports/
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neurologic disorders and age. However, as explanation of variance was comparable between the WMH score and 
the global SVD score, it seems that WMH is the major driving force to impact gait function in a sample of healthy 
community-dwelling subjects18,19,34. This likely comes from the associated rather diffuse and widespread effects of 
such abnormalities17,35 while other SVD features (e.g. lacunes or microbleeds) may have been not severe enough 
to cause a functional impact on their own.
To allow for further appreciation of the impact of SVD severity and comparison with the above mentioned 
studies, we additionally examined the relationship between gait and balance when considering only subjects with 
moderate to severe SVD scores (global SVD score > = 2). Prediction improved substantially for gait speed, show-
ing that the global SVD score accounted for 6.4% of the variance in addition to NBV (6%), whereas demographics 
and risk factors did not add to the explanation. Furthermore, in this more severely impaired cohort the impact 
WMH (score or volume) did not reach significance, suggesting the occurrence of additive damaging effects of 
multiple single SVD features on gait function and it is probably in this setting where a global SVD score may be 
of value.
Opposed to patient cohorts, other variables such as physical fitness, visual acuity, chronic pain or cognitive 
function might stronger influence gait and balance function. However, as the main focus of our study was exam-
ining the relationship between single compared to combined SVD markers with and gait or balance function, we 
focused on the major variables influencing gait and balance function (e.g. age, sex, vascular risk factors) in our 
study. Secondly, the clinical scores used to assess balance function seem to be insensitive to capture SVD related 
balance impairments, which are likely to be rather subtle in healthy community-dwelling subjects, presenting ear-
lier stages of SVD36. Compared to prediction of gait speed, results for the chair-stands test and standing balance 
test were less conclusive. Performance on the chair-stands test might be stronger dependent on physical factors 
(e.g. fitness, muscle, lung function)37. Also, a more detailed assessment of standing balance (such as dynamic 
posturography)38 might be needed. The ordinal scale of the standing balance test might not be sensitive enough 
to assess balance impairment in our sample and more informative for clinical cohorts.
Surprisingly, despite the narrow range (71–74 years), age was still a significant contributor to the variance 
explained in gait function. Hence, controlling for age effects seems to be crucial in advanced age, even in a very 
narrow age-range birth cohort17. Also a previous study4 showed that gait disorders are prevalent in about 11% of 
60–69 year old subjects, rising to 38% in 70–79 year old subjects, suggesting a steep increase of gait impairment 
from one decade to another. Furthermore and in line with previous studies, high blood pressure6 predicted worse 
performance in gait function.
MRI parameters R2 βj p
Gait speed
 WMH volume cm3 2.3 0.16 0.001*
 NBV 0.6 − 0.09 0.036
 WMH score 1.3 0.12 0.001*
 CMB sum ns 0.344
 Lac sum ns 0.574
 PVS ns 0.069
 global SVD score 1.4 0.13 0.000*
Chair-Stands
 WMH volume cm3 ns 0.084
 NBV ns 0.687
 WMH score 0.7 0.09 0.027
 CMB sum ns 0.207
 Lac sum ns 0.562
 PVS ns 0.279
 global SVD score 0.6 0.09 0.028
Balance
 WMH volume cm3 ns 0.999
 NBV ns 0.505
 WMH score ns 0.983
 CMB sum ns 0.999
 Lac sum ns 0.997
 PVS ns 0.999
 global SVD score ns 0.877
Table 3.  Association of SVD related abnormalities with gait, chair-stands and balance test. Adjusted R2 
(explanation of variance) and standardized beta-values (βj) are presented for significant findings only. Results 
marked with an asterisk (*) indicate significance with application of a Bonferroni-adjusted level of significance 
(0.007). Lac = Lacunes of presumed vascular origin, CMB = cerebral microbleeds, NBV = brain volume 
normalized by intracranial volume in %, PVS = perivascular spaces in basal ganglia, WMH = white matter 
hyperintensities.
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Although studies have reported associations between atrophy and SVD13,14, specifications and defined cut-offs 
regarding whether atrophy is related to “normal” aging or SVD are missing. Therefore, in this study, we focused 
on the focal SVD markers only. Nevertheless, we included total brain volume in our hierarchical regression analy-
sis and found that SVD-related brain changes and brain volume are both significantly, but independently explain 
gait function.
In conclusion our study confirms a negative impact of SVD-related morphologic brain changes on gait speed 
in addition to age, sex and hypertension and independent from normalized brain volume. The presence of WMH 
seems to be the major driving force for gait impairment in healthy elderly subjects.
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